Diclofenac and its derivatives as tools for studying human cytochromes P450 active sites: particular efficiency and regioselectivity of P450 2Cs
- PMID: 10572000
- DOI: 10.1021/bi991195u
Diclofenac and its derivatives as tools for studying human cytochromes P450 active sites: particular efficiency and regioselectivity of P450 2Cs
Abstract
A comparison of the oxidations of diclofenac with microsomes of yeasts expressing various human liver cytochromes P450 showed that P450 2C9 regioselectively led to 4'-hydroxy diclofenac (4'-OHD) whereas P450 3A4 only led to 5-hydroxy diclofenac (5-OHD). P450 2C19, 2C18, and 2C8 led to the simultaneous formation of 4'-OHD and 5-OHD (respective molar ratios of 1.3, 0.37, and 0.17), and P450 1A1, 1A2, 2D6, and 2E1 failed to give any detectable hydroxylated metabolite under identical conditions. P450 2C9 was found to be much more efficient for diclofenac hydroxylation than all the other P450s tested (k(cat)/K(M) of 1.6 min(-1) microM(-1) instead of 0.025 for the second more active P450), mainly because of markedly lower K(M) values (15 +/- 8 instead of values between 170 and 630 microM). Oxidation of diclofenac with chemical model systems of cytochrome P450 based on iron porphyrin catalysts exclusively led to the quinone imine derived from two-electron oxidation of 5-OHD, in an almost quantitative yield. Two derivatives of diclofenac lacking its COO(-) function were then synthesized; their oxidation by recombinant human P450 2Cs always led to a major product coming from their 5-hydroxylation. Substrate 2, which derives from reduction of the COO(-) function of diclofenac to the CH(2)OH function, was studied in more detail. All the P450s tested (1A1, 1A2, 2C8, 2C9, 2C18, 2C19, 2D6, and 3A4) almost exclusively led to its 5-hydroxylation. P450s of the 2C subfamily were found to be the most efficient catalysts for this reaction, with k(cat)/K(M) values between 0.2 and 1.6 min(-1) microM(-1). Oxidation of 2 with an iron porphyrin-based chemical model of cytochrome P450 also led to a product derived from the oxidation of 2 at position 5. These results show that oxidation of diclofenac and its derivative 2, either with chemical model systems of cytochrome P450 or with recombinant human P450s, generally occurs at position 5. This position, para to the NH group on the more electron-rich aromatic ring of diclofenac derivatives, is thus, as expected, the privileged site of reaction of electrophilic, oxidant species. The most spectacular exception to this chemoselective 5-oxidation of diclofenac derivatives was found for oxidation of diclofenac itself with P450 2C9 (and P450 2C19 and 2C18 to a lesser extent), which only led to 4'-OHD. A likely explanation for this result is a strict positioning of diclofenac in the P450 2C9 active site, via its COO(-) function, to completely orientate its hydroxylation toward position 4', which is not chemically preferred. P450 2C19, 2C18, and 2C8 would not lead to such a strict positioning as they give mixtures of 4'-OHD and 5-OHD. The above results show that diclofenac derivatives are interesting tools to compare the active site topologies of human P450 2Cs.
Similar articles
-
Comparison of the substrate specificities of human liver cytochrome P450s 2C9 and 2C18: application to the design of a specific substrate of CYP 2C18.Biochemistry. 1999 Jun 15;38(24):7828-36. doi: 10.1021/bi9903289. Biochemistry. 1999. PMID: 10387023
-
Synthesis of sulfaphenazole derivatives and their use as inhibitors and tools for comparing the active sites of human liver cytochromes P450 of the 2C subfamily.J Med Chem. 2001 Oct 25;44(22):3622-31. doi: 10.1021/jm010861y. J Med Chem. 2001. PMID: 11606127
-
Oxidation of tienilic acid by human yeast-expressed cytochromes P-450 2C8, 2C9, 2C18 and 2C19. Evidence that this drug is a mechanism-based inhibitor specific for cytochrome P-450 2C9.Eur J Biochem. 1996 Nov 1;241(3):797-804. doi: 10.1111/j.1432-1033.1996.00797.x. Eur J Biochem. 1996. PMID: 8944768
-
The metabolism of diclofenac--enzymology and toxicology perspectives.Curr Drug Metab. 2003 Aug;4(4):319-29. doi: 10.2174/1389200033489398. Curr Drug Metab. 2003. PMID: 12871048 Review.
-
Pharmacogenetics of CYP2C subfamily in a Japanese population.J Toxicol Sci. 1998 Jul;23 Suppl 2:129-31. doi: 10.2131/jts.23.supplementii_129. J Toxicol Sci. 1998. PMID: 9760448 Review. No abstract available.
Cited by
-
Role of conserved Asp293 of cytochrome P450 2C9 in substrate recognition and catalytic activity.Biochem J. 2003 Mar 15;370(Pt 3):921-6. doi: 10.1042/BJ20021841. Biochem J. 2003. PMID: 12482324 Free PMC article.
-
Quantum mechanics/molecular mechanics modeling of regioselectivity of drug metabolism in cytochrome P450 2C9.J Am Chem Soc. 2013 May 29;135(21):8001-15. doi: 10.1021/ja402016p. Epub 2013 May 16. J Am Chem Soc. 2013. PMID: 23641937 Free PMC article.
-
Optimization of the bacterial cytochrome P450 BM3 system for the production of human drug metabolites.Int J Mol Sci. 2012 Nov 28;13(12):15901-24. doi: 10.3390/ijms131215901. Int J Mol Sci. 2012. PMID: 23443101 Free PMC article. Review.
-
Pharmacokinetics of diclofenac and inhibition of cyclooxygenases 1 and 2: no relationship to the CYP2C9 genetic polymorphism in humans.Br J Clin Pharmacol. 2003 Jan;55(1):51-61. doi: 10.1046/j.1365-2125.2003.01712.x. Br J Clin Pharmacol. 2003. PMID: 12534640 Free PMC article.
-
Establishment of a transgenic cell line stably expressing human cytochrome P450 2C18 and identification of a CYP2C18 clone with exon 5 missing.World J Gastroenterol. 2002 Oct;8(5):888-92. doi: 10.3748/wjg.v8.i5.888. World J Gastroenterol. 2002. PMID: 12378636 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Miscellaneous